PTC Therapeutics Inc 2026年季度报告

FORM10-Q (Mark One) ☑QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGEACT OF 1934 For the quarterly period ended June30,2026 or ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIESEXCHANGE ACT OF 1934 Commission file number: 001-35969 PTC Therapeutics,Inc.(Exact name of registrant as specified in its charter) 04-3416587 Delaware Securities registered pursuant to Section12(b)of the Act: Name of each exchange on whichregistered Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of theSecurities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the registrant wasrequired to file such reports), and (2)has been subject to such filing requirements for the past 90days. YesNo☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for suchshorter period that the registrant was required to submit such files). YesNo☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, asmaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “acceleratedfiler,” “smaller reporting company,” and "emerging growth company" in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transitionperiod for complying with any new or revised financial accounting standards provided pursuant to Section13(a)of theExchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No As of July29, 2026, there were 83,460,802 shares of Common Stock, $0.001 par value per share, outstanding. TABLE OF CONTENTSPTC Therapeutics,Inc. PART I—FINANCIAL INFORMATION Item1. Financial Statements (unaudited)4Item2. Management’s Discussion and Analysis of Financial Condition and Results ofOperations36Item3. Quantitative and Qualitative Disclosures About Market Risk54Item4. Controls and Procedures55PART II—OTHER INFORMATIONItem1. Legal Proceedings55Item1A. Risk Factors55Item5. Other Information55Item6. Exhibits57 FORWARD-LOOKING STATEMENTS This Quarterly Report on Form10-Q contains forward-looking statements that involve substantial risksand uncertainties. All statements, other than statements of historical facts, contained in this QuarterlyReport on Form10-Q, including statements regarding our strategy, future operations, future financialposition, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,”“plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “aim,”and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form10-Q include, among other things,statements about: ●the outcome of pricing, coverage and reimbursement negotiations with third party payors for ourproducts or product candidates that we commercialize or may commercialize in the future;●expectations with respect to Sephience™ (sepiapterin) for the treatment of phenylketonuria, orPKU, including commercialization and the potential achievement of sales milestones andcontingent payments that we may be obligated to make;●our ability to maintain marketing authorization of Translarna™ (ataluren) for the treatment ofnonsense mutation Duchenne muscular dystrophy, or nmDMD, in geographies in which it hasapproval, including the effect of the European Commission's adoption of the negative opinionfrom the Committee for Medicinal Products for Human Use on Translarna, and the impact of thewithdrawal of the Translarna new drug application in the United States, on existing approvals;●the ability and willingness of individual countries within the European Union, or EU, to leverageArticles 117(3) and 5(1) of the EU Directive 2001/83 to allow continued commercial use ofTranslarna;●expectations with respect to our license and collaboration agreement with NovartisPharmaceuticals Corporation, or Novartis, for votoplam for the treatment of Huntington's disease,including our right to receive development, regulatory and sales milestones, profit sharing androyalty payments from Novartis, the design and expected timing of clinical trials and studies, theavailability of data, and regulatory submissions and responses, including potential acceleratedapproval;●expectations with respect to vatiquinone for the treatment of Friedreich’s ataxia, including withrespect to the design and expected timing of clini